(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Vietnam rethinks its flood strategy as climate change drives storms and devastation - 2The most effective method to Settle on Informed Conclusions about Senior Insuranc.
- 3Vote In favor of Your Favored Shimmering Water
- 4Overlooked infertility care should be part of national health services, says WHO
- 5What Yogurt Types Do You Know
- Figure out What Experience Level Means for Medical caretaker Compensation Dealings
- The Best Business visionaries Under 30
- Famous SUVs With Low Energy Utilization In 2024
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Moving Pool Highlights for 2024
- 7 Fast Approaches to Let loose Space on Your Telephone in a flash
- Very good quality Greens All over The Planet
- What we know about the Brown University shooting suspect who was found dead, and how police linked him to the MIT killing
- Find the Effect of Web-based Entertainment on Society: Exploring the Computerized Scene
